Short Bowel Syndrome Market Forecasts from 2023 to 2028

The short bowel syndrome market was valued at US$4.833 billion in 2021.

The short bowel syndrome market is anticipated to grow at a steady pace throughout the forecasted period. The growing prevalence of gastrointestinal disorders due to changing lifestyles and the rising number of colon-in-continuity patients are the major growth drivers of the short bowel syndrome market. Moreover, the rising awareness about the treatment and government investments for research projects coupled with product launches by market players is further contemplated to boost the short bowel syndrome market.

Market Drivers

Rising Gastrointestinal Problems

The major cause of growing short bowel syndrome is rising gastrointestinal problems, Crohn's disease, and volvulus. According to the survey conducted by AGA Journals in 2020, around 40% of the population suffered from functional gastrointestinal disorders with 49% of women among total respondents. Short bowel syndrome by birth is also driving the market for instance, around 24.5 out of every 100,000 births have short bowel syndrome as per the study of Surgery Today in 2021. The most common gastrointestinal disorders reported by World Gastroenterology Organization are functional constipation with a prevalence rate of 11.7%, functional dyspepsia (7.2%), proctalgia (5.9%0) fugax (4.7), functional diarrhoea, and IBS. The higher prevalence rate of gastrointestinal disorders is leading to short-bowel syndrome thereby widening the short-bowel syndrome market size.

Increased Awareness among People

There are various organizations founded in past years to raise awareness about short bowel syndrome. An organization ATLAS was formed in 2016 to achieve the best treatment and care for intestinal failure patients. Moreover, it engages with European reference networks to advise the distribution of resources across Europe and trains clinicians to manage patients within the healthcare system. The Oley Foundation in collaboration with the American Society for Parenteral and Enteral Nutrition and Medscape released a roadmap for care transition in short bowel syndrome to increase the knowledge of patient burden in case of intestinal failure and demonstrate improved performance in September 2021. These types of awareness initiatives are expected to drive the short bowel syndrome market.

Multiple Associated Negative Health Effects

There are multiple negative effects associated with short bowel syndrome such as diarrhea, swelling in lower extremities, weight loss, fatigue, foul-smelling stools, heartburn, and much more. All these effects raise the problem of patients thereby pushing them for treatment and widening the short bowel syndrome market scope. If left untreated, it can cause severe health problems like anemia and kidney stones which may be life-threatening in rare cases. Thus, the numerous negative effects along with the increased awareness are anticipated to propel the short bowel syndrome market.

Market Opportunities

The changing lifestyle causing gastrointestinal problems leading to more short bowel syndrome cases provides a good opportunity to enter the short bowel syndrome market. Moreover, the research and clinical trials backed by Government funding for the treatment of sort bowel syndrome are further anticipated to boost the short bowel syndrome market. For instance, the European Union funded the INTENS project in 2021 to deliver functional small bowel that can treat patients with small bowel syndrome. Moreover, the increased awareness among people about the treatments and benefits further provides an opportunity to the short bowel syndrome market players.

Market Restraints

Apart from the growth factors, some restraining factors in the short bowel syndrome market are limiting the market growth. Lesser number of approved drugs in developing countries along with some side effects of medication such as nausea, headache, muscle pain, etc. Thus, the prescription of the medication must be done by carefully examining the benefits over side-effects and the average healthcare system in many under-developed nations limits the market scope for the short bowel syndrome market.

North America is expected to witness a notable CAGR

North American region is expected to hold a significant share of the short bowel syndrome market during the forecast period. The higher prevalence of SBS in the US and rising government investment are the major factors for such a significant share of the region. For instance, the National Institute of Health granted $1.3 million to Saint Louis University for Short Bowel Syndrome Research in April 2022. Moreover, the presence of major market players such as Ardelyx, and Sancilio and Company drives the short bowel syndrome market in the region as the company indulges in research and clinical trials for numerous treatments.

Short Bowel Syndrome Market Players

• Takeda Pharmaceutical Company is a research-driven multinational pharmaceutical company. The focus areas of the company are oncology, rare diseases such as short bowel syndrome, neuroscience, gastroenterology, plasma-derived therapies, and vaccines.
• OxThera Inc. is a Sweden-based biopharmaceutical company providing solutions for rare kidney diseases and genetic diseases. The company provides Oxabact for short bowel syndrome treatment which was granted orphan designation by the European Medicines Agency Committee for Orphan Medicinal Products.
• VectivBio AG is a clinical-stage company with a focus on developing transformative medicines for the treatment of severe rare diseases. The company provides Apraglutide drugs for patients with short bowel syndrome. It is a long-acting and synthetic GLP-2 analog that acts as a full agonist.

Market Developments

• In October 2022, Liraglutide's evaluation results from the Phase III EASE 1 clinical study for the treatment of short bowel syndrome (SBS) patients were released by Zealand Pharma. Almost 65% of candidates showed a positive response to all the candidates dosing twice weekly with glepaglutide.
• In June 2021, VectivBio announced the Phase 2 STARS nutrition metabolic balance study to evaluate the apraglutide in colon-in-continuity (CIC) patients with intestinal failure. The study's goal is to demonstrate how apraglutide helps CIC patients' intestinal absorption.

Segmentation:

By Product Type

• Glucagon-like Peptide-2 (GLP2)
• Growth Hormone
• Glutamine
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Sales

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others